Applications of cefalotin sodium in anti-leukemia drugs

A technology of cefalotin sodium and leukemia, which is applied in the field of medicine and can solve the problems that the application of cefalotin sodium has not been reported.

Inactive Publication Date: 2018-07-31
TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But so far, the application of cefalotin sodium in ant...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of cefalotin sodium in anti-leukemia drugs
  • Applications of cefalotin sodium in anti-leukemia drugs
  • Applications of cefalotin sodium in anti-leukemia drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some, not all, embodiments of the present invention. All other embodiments obtained by persons of ordinary skill in the art based on the embodiments of the present invention belong to the protection scope of the present invention.

[0018] Cefalotin sodium is:

[0019]

[0020] The CAS number of the cefalotin sodium involved in the present invention is 58-71-9, which is provided by the High-throughput Drug Screening Center of the Tianjin International Joint Research Institute of Biomedicine.

[0021] In the present invention, method steps such as expression and purification of histone lysine methyltransferase DOT1L in proteins related to mixed lineage leukemia and compound screening methods reference methods (Basavapa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides applications of cefalotin sodium in preparation of drugs used for preventing or treating leukemia, and especially applications of cefalotin sodium in preparation of drugs used for preventing or treating mixed-lineage leukemia (MLL). According to an application method, histone lysine methyltransferases DOT1L participating in gene rearrangement of mixed-lineage leukemia is taken as a target protein, SPR technology is adopted, and cefalotin sodium with inhibition effect on the target protein is selected as an inhibitor; cefalotin sodium is combined with the target protein so as to inhibit the activity of the target protein, prevent participation of DOT1L in MLL gene rearrangement process, and prevent and treat leukemia. The invention also provides a drug used for preventing or treating leukemia.

Description

technical field [0001] The invention relates to the field of medicines, in particular to the application of cefalotin sodium in anti-leukemia medicines Background technique [0002] Mixed lineage leukemia (Mixed Lineage Leukemia, MLL) is a hematological malignancy. It is named after the formation of MLL fusion protein after MLL gene rearrangement. The MLL gene is located on chromosome 11, zone 2, band 3 (11q23). Associated with hematologic malignancies. Acute leukemia positive for MLL gene rearrangement can occur from birth to adulthood, manifested as acute myeloid leukemia (AML) or acute lymphoblastic leukemia (acutelymphoblastic leukemia, ALL). Although there will be some errors, in a research survey of related literature, it was found that 11q23 chromosomal translocation or MLL gene rearrangement occurred in 22% of ALL patients after integrating the data of 7969 AML patients and 1252 ALL patients and 5.2% of AML patients. About 14% of children with acute myeloid leukem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/546A61P35/02
CPCA61K31/546A61P35/02
Inventor 杨诚刘祥徐晓林赵换李召
Owner TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products